Skye Bioscience, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-11. Between them they name 2 people, with 2 appointments and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Departing: John P. Sharp, Chief Financial Officer
On September 8, 2026, John P. Sharp resigned as Chief Financial Officer and principal financial and accounting officer of the Company, effective as of the Effective Date.
Appointed: Punit Dhillon, President and Chief Executive Officer, effective 2026-09-08
Appointment of Principal Financial and Accounting Officer In connection with Mr. Sharp's departure, on September 9, 2026, the Board of Directors of the Company appointed Punit Dhillon, the Company's President and Chief Executive Officer, as the Company's principal financial and accounting officer, effective as of September 8, 2026.
Appointed: John P. Sharp, Chief Financial Officer
The Repriced Options include underwater options held by Punit Dhillon, the Company's President and Chief Executive Officer and the principal executive officer, financial and accounting officer of the Company, and Tuan Diep, the Company's Chief Operating Officer, as set forth below: Name and Position Total Repriced Options Original Exercise Price of Repriced Options Punit Dhillon President and Chief Executive Officer 1,103,959 $2.89 to $14.56 Tuan Diep Chief Operating Officer 396,295 $2.89 to $14.56 Appointment of Chief Financial Officer On March 31, 2026, the Board appointed John P. Sharp as t
Find people with the same kind of experience as the Chief Financial Officer at Skye Bioscience, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Skye Bioscience, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Skye Bioscience, Inc. is in the news or changes leadership.
Get an alert when Skye Bioscience, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Skye Bioscience, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.